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WHAT DO WE MEAN BY RESEARCH
WITHOUT PRIOR CONSENT
(DEFERRED CONSENT)?
Emergency research with critically unwell
children is vital to make sure that the
most ill and injured children benefit from
evidence-based healthcare.1 Ethical guid-
ance require that consent be sought from
parents (or legal representatives) on
behalf of their children2 before research is
initiated, yet concerns about problems in
seeking parents’ consent when their child
is critically ill have been a significant
barrier to conducting clinical trials.3 4
Taking time out to seek informed consent
before starting treatment will often be dif-
ficult to justify as delaying any interven-
tion in an emergency could diminish a
child’s chances of recovery. Parents will
usually be highly distressed in a critical
care situation, and many will struggle to
make an informed decision about
research in the limited time available.
Many countries have legislated to
permit variations to informed consent
and allow progress in research to develop
critical care treatments.5–7 While the
details vary, a common feature is that
informed consent is not requested before
the patient receives the intervention
being researched.8 In the USA, the Food
and Drug Administration (FDA)
Exception from Informed Consent
(EFIC) essentially ‘waives’ informed
consent, although practitioners must
show that they have attempted to contact
legal representatives and tried to provide
the opportunity to ‘opt out’ of a trial.5 9
The FDA’s detailed guidance aims to
assist researchers in implementing
EFIC,10 11 although the accompanying
public consultation requirements have led
to varied practice and costly delays in
setting up trials.12
Across European Union countries, legis-
lation7 13 enables practitioners to conduct
research without seeking prior informed
consent from parents when certain condi-
tions are met (see box 1 for UK example).
No accompanying guidance has been
made available to assist researchers in
implementing the legislation. European
legislation does not name this alternative
to informed consent, but it is commonly
called ‘deferred consent’. We would argue
that this is a misnomer as a child will
have already received an intervention as
part of a trial before any information is
given or consent is sought. Essentially
permission is sought post-intervention to
use data that have already been collected
and consent for the child to continue to
take part in the trial. These problems
with the terminology have led to much
discussion recently, leading to a move
towards the term ‘research without prior
consent’, as it more accurately reflects the
process of consent seeking in critical care
research. We will, therefore, use the latter
term for the rest of this article. However,
regardless of what terminology is used,
research without prior informed consent
can be seen as eroding the autonomy of
parents and children and has been much
debated.14–18
HAVE ANY TRIALS BEEN CONDUCTED
WITHOUT PRIOR CONSENT?
Although a number of adult critical care
trials have been conducted without prior
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consent over the last decade,19 20 the CATheter infec-
tions in CHildren trial (CATCH)21 was one of the
first UK paediatric trials to use this approach since
legislation changes in 2008. Another National
Institute for Health Research-funded multicentre trial
investigating the Emergency treatment with
Levetiracetam or Phenytoin in Status Epilepticus,22 23
which is using research without prior consent, has
recently opened to recruitment. The number of trials
using this approach is expected to increase over the
next few years. It will be important to share experi-
ences of conducting these challenging trials to inform
peer and Research Ethics Committee reviews.
WHAT DO PARENTS AND PRACTITIONERS THINK
ABOUT RESEARCH WITHOUT PRIOR CONSENT?
In the CONsent methods in childreN’s emergEncy
medicine and urgent Care Trials (CONNECT) study,
we found that many parents recruited to CATCH
were momentarily shocked or surprised to discover
that their child had been entered into a trial without
their consent, although they did not voice this to prac-
titioners.24 After hearing practitioners explain why
research without prior consent is being used in their
situation—that it enables vital research to take place
in time-critical situations—parents’ initial concerns
were dispelled. Practitioners’ explanations were
important to parents and helped to reassure them that
there were good reasons for doing research without
prior consent. Gauging the right moment to approach
parents to discuss research is important—we found
that mistiming the approach could add to parents’
distress.
Despite its ‘do then ask’ sequence, parents with
experience of research without prior consent told us
they felt their decisions about their child’s participa-
tion had been voluntary. CONNECT and other
research25 26 have shown that parents support
research without prior consent and appreciate the
reasons for using it as long as their child’s safety is not
compromised. However, parents’ support for this
approach may have its limits and is related to what is
being trialled. Most parents in CONNECT remarked
that they would be concerned about not seeking prior
consent in trials involving either ‘new’ drug
interventions that were not already used in clinical
care or other potentially significant changes in clinical
practice.23 24
Practitioners’ views on research without prior
consent differed depending upon whether or not they
had experience of this method.27 Practitioners with
no experience of research without prior consent were
concerned that it would be detrimental to the parent–
practitioner relationship. In contrast, practitioners
with experience of this approach described how fam-
ilies were receptive to the method as long as discus-
sions were appropriately timed and conducted
sensitively.
We drew on the CONNECT study findings in light
of bioethical principles, including voluntariness,
autonomy, non-maleficence and justice,18 28 to
produce guidance on approaches to critical care
research without prior informed consent.
WHEN SHOULD I APPROACH PARENTS TO
DISCUSS RESEARCH WITHOUT PRIOR CONSENT?
CONNECT guidance recommends explaining what
has happened at the earliest appropriate opportunity,
which is likely to be after the initial emergency situ-
ation has passed. In such clinical situations, parents
often rapidly form a close relationship with the child’s
nurse. Consulting with nursing staff about the child’s
Box 1 Research without prior consent (deferred
consent) can be conducted when the following
conditions are met
1. Treatment is required urgently
2. Urgent action is required for the purposes of the trial
3. It is not reasonably practicable to obtain consent
prospectively
4. An ethics committee has given approval to the pro-
cedure under which the action is taken.13
Box 2 Key points to cover when discussing
research without prior consent with parents
▸ Why the research is being conducted and why their
child’s condition made him/her eligible for the trial.
▸ That it was not possible to seek consent before the
research intervention was given because their child
needed immediate treatment, and it was not safe to
delay this.
▸ That their permission is being sought to use informa-
tion and/or samples that have already been collected
and for their child to continue in the research.
▸ Details of how the intervention is already used in
clinical practice (if applicable), any changes to clinical
practice and potential risks of being in the research.
▸ That the research has been approved by an independ-
ent research ethics committee whose role is to review
research to protect the rights, safety and well-being
of participants.
▸ How the research findings will inform future treat-
ments for critically ill children.
▸ That parents are free to choose whether or not their
child’s information is used in the research and that
their decision will not affect their child’s care.
▸ Details of any follow-up procedures arising from the
research (if applicable).
▸ Where further information can be found—for
example, leaflets, website, principal investigator.
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condition and how parents are coping will help gauge
when is an appropriate time.
HOW SHOULD I EXPLAIN TO PARENTS THAT
THEIR CHILD HAS BEEN ENTERED INTO
RESEARCH WITHOUT THEIR PRIOR INFORMED
CONSENT?
Ask a member of staff known to the family to intro-
duce you. Start by asking parents how their child is
doing and check whether it is a convenient time to
discuss research. Discuss key aspects of the trial,
showing parents (and children if appropriate—see
below) where information can be found on the
participant information leaflet, paying particular
attention to the key points shown in box 2. Allow
parents time to consider the information (overnight if
possible) and to ask questions about the trial. While it
may be important to seek permission to use data
already collected and consent for continued participa-
tion in the trial (and any follow-up procedures) before
the child is discharged from hospital, it is also import-
ant to allow time to explore parents’ views and under-
standing of the trial and follow-up procedures.
Be prepared to address concerns that participation
may have contributed to a poor recovery. It may help
to explain any potential risks associated with
Box 3 Options to consider when a child has died
Option 1: Approach parents to explain about the trial before they leave hospital
▸ Discuss the trial and provide information before parents leave hospital. However, only approach parents with informa-
tion and seek permission to use data already collected at this point if it is believed that parents have the capacity to
absorb information and make an informed decision.
Option 2: Explain about the trial by letter at a later date
▸ If it is not thought appropriate to explain about the trial or seek permission to use data already collected before
parents leave the hospital, consult with clinical colleagues and bereavement counsellors to identify an appropriate
time to contact parents via a posted letter. Sending the letter could be timed to coincide with the bereavement
follow-up invitation.
▸ The covering letter, information leaflet and consent form should be designed and worded specifically for bereaved
parents. It should be prepared at the trial design stage and written in close consultation with bereaved parents,
bereavement specialists and relevant special interest groups (see recommendation 1).
▸ The covering letter should be personalised and, if possible, signed by a clinician known to the family. The letter
should explain that, understandably, parents will often have questions about the research in the days, weeks or
months after the loss of a child and invite them to contact the trial team to arrange for a telephone or face-to-face
discussion with the principal investigator about the trial if they wish. Include the bereaved parent information leaflet,
consent form and stamped addressed envelope.
▸ At the outset of the trial, ethical approval may have been sought to include the anonymised data of deceased patients
in analyses should no consent form be received from bereaved parents. Therefore, letters to parents should explain
whether or not their child’s data will be included in the trial if parents do not respond to the letter.
▸ Copies of the letters and accompanying documents sent to parents should be placed in the patient’s notes.
▸ Be prepared to respond to parents who are concerned that research participation may have contributed to their child’s
death. Be careful to avoid giving false reassurance that this is not the case, unless it has been established by the prin-
cipal/chief investigator that the cause of death was not related to the trial.
Option 3: Contact parents by telephone or letter to arrange a face-to-face discussion about the trial
▸ If it is not thought appropriate to explain about the trial or seek permission to use data already collected before
parents leave the hospital, consult with clinical colleagues and bereavement counsellors to identify an appropriate
time to contact parents via telephone or letter to arrange a face-to-face visit to discuss research.
▸ The letter should be personalised, signed by a clinician (known to the family if possible) and include a bereaved
parent information leaflet.
▸ Copies of letters sent to parents should be placed in the patients’ notes.
▸ Provide parents with options for meeting location (eg, at their home or local hospital) as some parents may not wish
to return to the hospital where their child died.
▸ During face-to-face discussions, explore parents’ views and understanding of the trial and why consent was not
sought so that any concerns can be addressed.
▸ Be prepared to respond to parents who are concerned that trial participation may have contributed to their child’s
death. Be careful to avoid giving false reassurance that the trial did not contribute to their child’s death unless it has
been established by the principal/chief investigator that the cause of death was not related to the trial.
▸ If parents do not wish to have a face-to-face meeting, inform them that a trial information leaflet and consent form
will be sent via post (see option 2).
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participation in the trial, that the intervention is
already used in clinical practice (if applicable), and to
indicate that the research has been approved by a
Research Ethics Committee. It may also help to
explain that nobody will know which treatment is the
most effective until the trial has been completed
(which may take a few years) and to offer parents the
opportunity to speak to the principal investigator or
senior member of the research team to discuss any
concerns.
SHOULD I INVOLVE CHILDREN IN THE
DISCUSSION?
Although children (under 16 years) cannot legally
provide consent for their own participation in a trial,
decisions about research should be shared by children
and their parents29 if their maturity, condition and
cognitive capacity allows. Young people (aged 16–18
years)30 can legally provide their own consent for a
trial, although this is often impossible in an emer-
gency situation. When assent (for children) or consent
(for young people) cannot be sought due to their clin-
ical condition, provide a developmentally appropriate
information sheet to help parents discuss the research
with their child when they have recovered. Provide
contact details so that parents or children can discuss
any aspect of the trial with the research team at a later
date if they wish.
WHAT SHOULD HAPPEN IF A CHILD DIES BEFORE
PARENTS ARE APPROACHED ABOUT THE TRIAL?
Legislation7 13 does not stipulate what should happen
in circumstances where a child dies. As there is wide
variability and complexity of parental feelings about
research when a child has been enrolled in a study
and subsequently died, a one-size-fits-all approach to
discussing a clinical trial is unlikely to be sensitive to
the needs of grieving parents.31 Although there are
some exceptions,25 many bereaved parents wish to be
informed about their child’s involvement and pro-
vided with the opportunity to discuss having their
child’s data analysed in a trial.23 31 Talking with
recently bereaved parents about research in which
their child was involved will almost certainly be very
difficult for you and for parents. However, in the
interests of openness and honesty it is important to
offer the opportunity to do so, otherwise parents will
have no knowledge of their child’s participation in
research, nor can their child’s data be included in the
analyses. As well as potentially biasing the findings,32
this could be contrary to what parents would want for
their child’s data. Box 3 outlines some options to help
those involved decide how to approach bereaved
parents to discuss research without prior consent.
CONCLUSIONS
The CONNECT guidance will help practitioners to
conduct research without prior consent in a way that is
ethically appropriate and addresses the needs of fam-
ilies. Full CONNECT guidance can be found at https://
www.liv.ac.uk/psychology-health-and-society/research/
connect/ and will be reviewed and updated as further
evidence becomes available. Research is required to look
at the transferability of CONNECT guidance to other
study types and settings, including adult critical care.
Twitter Follow Kerry Woolfall at @CONNECTStudy, Follow
Mark Lyttle at @mdlyttle
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